UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                                 WASHINGTON D.C.

                                   FORM 10-QSB

|X|   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934, For the Quarter Ended March 31, 2005

|_|   Transitional Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                          Commission File No. 000-28459

                      ADVANCED PLANT PHARMACEUTICALS, INC.

             (Exact name of Registrant as specified in its charter)



              Delaware                            59-2762023
        -------------------                    -------------------
   (State  of other jurisdiction       (I.R.S. Employer Identification Number)
of  incorporation  or  organization)


                  43 West 33rd Street, New York, New York 10001
                 ----------------------------------------------
                     Address of principal executive offices

        Registrant's telephone number, including area code: 212-695-3334

      Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
issuer was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                 Yes |X| No |_|

      As of May 19, 2005, there were issued and outstanding 777,383,154, shares
of Common Stock, $.0007 par value per share.

             Transitional Small Business Disclosure Format

                                 Yes |_|  No |X|

<PAGE>

                      ADVANCED PLANT PHARMACEUTICALS, INC.

                                      INDEX
                                      -----

                                                                          PAGE
                                                                          NUMBER
                                                                      ----------

PART I.  FINANCIAL INFORMATION

Item 1.  Condensed financial statements

         Condensed Balance sheets as of March 31, 2005 (unaudited)
             and December 31, 2004 (audited)                                   3
         Condensed Statements of operations for the three months
             ended March 31, 2005 and 2004 (unaudited)                         4

         Condensed Statements of cash flows for the three months ended
             March 31, 2005 and 2004 (unaudited)                               5

      Notes to the condensed financial statements                              7

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                                  11

Item 3.   Controls and Procedures                                             15

PART II.  OTHER INFORMATION                                                   16

SIGNATURES                                                                    17


                                       2
<PAGE>

                                     PART I

ITEM 1. CONDENSED FINANCIAL STATEMENTS

Item 1. Financial Statements

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                     ASSETS
                                                                                           March 31,     December 31,
                                                                                             2005            2004
                                                                                         ------------    ------------
                                                                                           Unaudited
<S>                                                                                      <C>             <C>
CURRENT ASSETS
  Cash and cash equivalents                                                              $        642    $      1,045
    Accounts receivable
   Inventory                                                                                    1,391             306
                                                                                         ------------    ------------
         Total Current Assets                                                                   2,033           1,351

OFFICE EQUIPMENT, net of accumulated depreciation of $2,103
    and $1,824, respectively                                                                    2,250           2,529
OTHER ASSETS
    Goodwill                                                                                   10,406          10,406
   Intangible assets, net of impairment losses                                                 20,020
    Prepaid and other assets                                                                    7,144           7,144
                                                                                         ------------    ------------
                                                                                               37,570          17,550
                                                                                         ------------    ------------
          Total Assets                                                                   $     41,853    $     21,430
                                                                                         ============    ============

                    LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES
   Bank overdraft                                                                        $      7,402    $      5,111
   Accounts payable                                                                           174,794         167,108
   Accrued expenses                                                                           580,729         568,983
   Accrued expenses - stockholders                                                            946,796         901,246
    Due to distributor                                                                        103,500         103,500
    Due to stockholder - asset acquisition                                                  1,315,000       1,315,000
   Loans payable - stockholders                                                               337,646         228,796
                                                                                         ------------    ------------
         Total Current Liabilities                                                          3,465,867       3,289,744

STOCKHOLDERS' DEFICIENCY
    Preferred stock, authorized 10,000,000 shares; $0.0007 par value; 5,000,000
        and 2,500,000 shares issued and outstanding at March 31, 2005 and December 31,
        2004 respectively                                                                       3,500           1,750
   Common stock, authorized 880,000,000 shares; $0.0007 par value; 788,157,996
        and 748,157,996 shares issued and outstanding at
        March 31, 2005 and December 31, 2004 respectively                                     551,711         523,711
   Additional paid-in capital                                                              14,656,976      14,540,226
   Accumulated deficit                                                                    (18,636,201)    (18,334,001)
                                                                                         ------------    ------------

    Total Stockholders' Deficiency                                                         (3,424,014)     (3,268,314)
                                                                                         ------------    ------------
          Total Liabilities and Stockholders' Deficiency                                 $     41,853    $     21,430
                                                                                         ============    ============
</TABLE>


                 See accompanying notes to financial statements.



                                       3
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

<TABLE>
<CAPTION>
                                                   For the Three Months Ended
                                                           March 31,
                                                      2005             2004
                                                  -------------    -------------
                                                                     Restated
<S>                                               <C>              <C>
REVENUE - SALES                                   $       2,130    $      17,158
COSTS AND EXPENSES
    Cost of goods sold                                    1,122           19,705
   Selling, general and administrative expenses         196,449        1,902,263
   Stock issued for marketing services                  106,500          731,700
   Stock issued for consulting services                     303           56,700
   Depreciation                                             279               65
                                                  -------------    -------------

           Total Costs and Expenses                     304,653        2,710,433
                                                  -------------    -------------

NET LOSS                                          $    (302,523)   $  (2,693,275)
                                                  =============    =============

NET LOSS PER SHARE OF COMMON
   STOCK (basic and fully diluted)                $        (.00)   $        (.01)
                                                  =============    =============

WEIGHTED AVERAGE NUMBER OF COMMON
   SHARES OUTSTANDING (basic and fully diluted)     786,269,107      559,127,170
                                                  =============    =============
</TABLE>

                 See accompanying notes to financial statements.


                                       4
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<TABLE>
<CAPTION>
                                                             For the Three Months Ended
                                                                      March 31,
                                                                2005            2004
                                                             -----------    -----------
                                                                               Restated
<S>                                                          <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
   Net loss                                                  $  (302,523)   $(2,693,275)
   Stock issued for services                                     106,803        788,400
   Depreciation expense                                              279             65
   Changes in assets and liabilities:
       Decrease in accounts receivable                               306
       Increase (decrease) in inventory                           (1,391)        53,841
       Increase in other assets                                                 (23,000)
     Increase (decrease) in accounts payable                       7,686       (108,852)
     Increase in accrued expenses                                 11,746      1,771,970
     Increase in accrued expenses - stockholders                  55,550         42,160
                                                             -----------    -----------
       Net cash used in operating activities                    (121,544)      (168,691)

CASH FLOWS FROM INVESTING ACTIVITIES
   Cash paid for office equipment                                                (1,289)
   Cash paid for intangible assets                                (1,000)
   Due from related parties                                                      11,738
                                                             -----------    -----------
       Net cash (used in) provided by investing activities        (1,000)        10,449

CASH FLOWS FROM FINANCING ACTIVITIES
   Bank overdraft                                                  2,291
   Cash acquired in acquisition of subsidiary                                       100
   Loans payable - stockholders' - net                            99,850        (16,000)
   Due to related company                                                         4,836
   Proceeds from issuance of common stock                         20,000         70,000
                                                             -----------    -----------

       Net cash provided by financing activities                 122,141         58,936
                                                             -----------    -----------

       Net (decrease) increase in cash                              (403)       (99,306)

CASH AT BEGINNING OF PERIOD                                        1,045        265,858
                                                             -----------    -----------

CASH AT END OF PERIOD                                        $       642    $   166,552
                                                             ===========    ===========
</TABLE>

                 See accompanying notes to financial statements.


                                       5
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

                CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

<TABLE>
<CAPTION>
                                                                            For the Three Months Ended
                                                                                    March 31,
                                                                                2005         2004
                                                                              ---------    ---------
                                                                                           Restated
<S>                                                                           <C>          <C>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

   NON-CASH INVESTING AND FINANCING ACTIVITIES

     Issuance of common stock for services                                    $ 106,803    $ 788,400

     Issuance of preferred stock in payment of loans payable
          to stockholders                                                        10,000

      Issuance of preferred stock in payment of accrued expenses
        to stockholders                                                          10,000

     Purchase of intangible assets for loan payable to stockholder               19,000

      Assets acquired and liabilities assumed in acquisition of subsidiary:

       Cash acquired                                                                             100
       Goodwill                                                                                9,041
       Accrued expenses                                                                       (8,251)
       Loans payable - stockholders                                                             (890)
</TABLE>

                 See accompanying notes to financial statements.


                                       6
<PAGE>

1. CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company, the accompanying unaudited condensed financial
statements include all adjustments (consisting only of normal recurring
accruals) which are necessary for a fair presentation of the results for the
periods presented. Certain information and footnote disclosure, normally
included in the financial statements prepared in accordance with generally
accepted accounting principles, have been condensed and omitted. The results of
operations for the three months ended March 31, 2005 are not indicative of the
results of operations for the year ended December 31, 2005. The condensed
financial statements should be read in conjunction with the Company's financial
statements included in its annual Form 10 KSB for the year ended December 31,
2004.

2. STOCK WARRANTS

At March 31, 2005, the Company had outstanding warrants to purchase 7,000,000
shares of the Company's common stock at a price of $.03 per share. The warrants
are exercisable and expire at various dates through 2007.

3. COMMITMENTS AND CONTINGENCIES

The Company has employment agreements with three employees, and a consulting
contract with a key consultant, who are also stockholders of the Company. At
March 31, 2005, the Company has a total liability for accrued salaries and
consulting expense to stockholders of $757,800. There could be certain payroll
tax liabilities owed to the IRS on some of the payments for services to certain
consultants that were paid in prior years, pursuant to these employment
agreements.

4. RELATED-PARTIES STOCK AND ASSET TRANSACTIONS

On January 18, 2005, the Company issued 30,000,000 shares of its common stock
under an S-8 filing with the Securities and Exchange Commission to consultants
at $0.00355 per share. The aggregate remuneration of $106,500 has been treated
as stock issued for marketing services and expensed in the current year.

In connection with a private placement, on January 24, 2005 the Company issued
10,000,000 shares of its common stock at $0.002 per share realizing $20,000.

On February 1, 2005, the Company issued 2,500,000 shares of its preferred stock
at $0.008 per share as payment of $20,000 against loans payable - stockholders
and accrued expenses - stockholders.

On March 5, 2005, Amazing, a subsidiary of the Company, entered into an
Agreement of Sale with Nature's Backyard, Inc., whereby Amazing agreed to buy
all intellectual property, permits, patents (granted, pending, or applied for),
trademarks, processes, formulation, exact ingredients, precise way of
manufacturing, and related items of the "Slim Cookie", a product for weight loss
and lowering cholesterol. The purchase price is as follows: (a) Payment of
$1,000 and the issuance of 200,000 shares of common stock on signing the
agreement, (b) 300,000 shares of common stock upon signing and filing of a
provisional patent application by the Company, (c) 100,000 shares of common
stock upon the issuance of a patent by the U.S. Patent and Trademark Office, (d)
payment of $4,000 not more than 60 days from the execution of the Agreement, and
(e) payment of $15,000 within 270 days of the execution of the Agreement.

5. SUBSEQUENT EVENTS

On April 26, 2005, the Company issued 4,000,000 shares of its common stock under
an S-8 filing with the Securities and Exchange Commission to consultants at
$0.00345 per share. The aggregate remuneration of $13,800 will be treated as
stock issued for marketing services and expensed in the current year.

On April 26, 2005, the Company issued 5,000,000 shares of its common stock under
an S-8 filing with the Securities and Exchange Commission at $0.00345 per share
as payment for accounts payable.


                                       7
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

Background

Advanced Plant Pharmaceuticals, Inc. (the "Company") was incorporated in the
State of Delaware in 1986, under the name Ventra Management, Inc. On July 20,
1994, we amended our Certificate of Incorporation to change our name to Advanced
Plant Pharmaceuticals, Inc.

Description of Business

The Company continues to focus on the research and development of plant based
dietary supplements. In July 1999, the Company acquired exclusive rights and
interests to a thirteen-step process, which utilizes virtually all of the
nutrients found in plants to manufacture natural herbal dietary supplements. The
purchase price for the thirteen step process was 12,000,000 shares of common
stock of the Company. The shares were issued on February 13, 2001. Further, the
Company is required to issue an additional 6,000,000 shares of common stock when
marketing of the product commences. The Company intends to use this process to
manufacture products that it hopes to distribute worldwide through various sales
distribution contracts.

On February 28, 2000, the Company entered into an Asset Purchase Agreement with
Dr. Bielory to purchase his various allergy and nasal formulations. This
agreement was approved by the Board of Directors on September 6, 2000. Dr.
Bielory was granted a five year option to purchase an aggregate of 18,000,000
shares of the Company's common stock at an exercise price of $180.00. Dr.
Bielroy exercised an option for 12,000,000 shares in the first quarter of 2001.

Sinusol, being the formulation purchased from Dr. Bielory, is a generalized base
solution for the development of an extensive line of specialty products related
to allergy and sinus conditions. The ingredients include a mixture of gently
pH-balanced essential mineral oils that combat the various symptoms related to
allergies and sinus disorders, including congestions, irritated nasal mucosa and
bacterial and fungal infections. Specialized advanced formulations are being
reviewed for patent submission.

In addition to Sinusol, the Company is also currently marketing its Lo-Chol
product. Lo-Chol's formula is derived from the "whole plant" parts of six
selected plants that work in concert to help tip your lipid balance (good and
bad cholesterol) towards a more normal level. These six plants are
synergistically combined using a proprietary "whole plant technology" (a special
pharmaceutical-grade process) that delivers virtually all the natural
phyto-chemicals and active ingredients in the plants. Unlike almost all other
herbal supplements on the market, Lo-Chol does not contain any extracts.
Instead, it utilizes the entire part of a specific plant that is processed and
standardized to deliver optimum potency and nutritional benefits.

Recent Developments

In January 2004, the Company acquired a 44% interest in Amazing Nutritionals,
Inc., a development stage company, whereby APPI sold Amazing all of the rights,
title, patents, trademarks, processes and related items of LHM123 which is a
natural composition for the treatment of senile dementias in consideration for
3,300,000 shares of Amazing's common stock.

In December 2004, the Company acquired a 99% interest in Mazal Plant
Pharmaceuticals, Inc., a development stage company, whereby APPI sold Mazal all
of its rights relating to or connected with developing, manufacturing and
distributing of three of its products, plant based compositions designed to
treat elevated cholesterol, leukemia and Alzheimer's disease in consideration
for 7,000,000 shares of Mazal's common stock and an amount due from Mazal of
$50,000.

Results of Operations

Results of Operations - Three Months Ended March 31, 2005 Compared to the Three
Months Ended March 31, 2004.

Revenues

Revenues generated during the three months ended March 31, 2005, aggregated
$2,130, as compared to $17,158 for the three months ended Mach 31, 2004. The
decrease of $15,028 in revenues from the comparable period in the prior year is
primarily due to the termination of Ed McMahon as spokesperson. We believe the
trend in decreased revenues will not continue if we are able to engage a new
spokesperson for our products.


                                       8
<PAGE>

Costs of Goods Sold

Cost of Goods Sold for the three months ended March 31, 2005 aggregated $1,122
as compared to $19,705 for the three months ended March 31, 2004. The decrease
for the three months ended March 31, 2005 is the result of a decrease in sales
of our products.

Operating Expenses

Operating Expenses incurred for the three months ended March 31, 2005,
aggregated $303,531 as compared to $2,690,728 for three months ended March 31,
2004, which is a decrease of $2,387,197. This decrease was primarily due to a
decrease in the issuance of stock for services which was off set by an increase
in cost of good sold, selling general and administrative expenses and an
impairment loss. We expect the decrease in our cost and expenses to continue as
we expect to be able to continue to curtail the issuance of stock for services.

Net Loss and Loss Per Common Share

The net loss and the loss per common share was $302,523 and $.00 for the three
months ended March 31, 2005, as compared to net loss of $2,693,275 and $.01 for
the three months ended March 31, 2004. This decrease was due primarily to a
decrease in the issuance of stock for services.

Liquidity and Capital Resources

At March 31, 2005, we had working capital deficit of $3,463,834 as compared with
$3,288,393 at December 31, 2004. The increase in the working capital deficit is
primarily the result of an increase in accrued expenses.

We have historically sustained our operations and funded our capital
requirements with the funds received from the sale of our products, loans
received from related parties and the sale of our securities. We will still need
additional investments in order to continue operations. Additional investments
are being sought, but we cannot guarantee that we will be able to obtain such
investments.

Financing transactions may include the issuance of equity or debt securities,
obtaining credit facilities, or other financing mechanisms. However, the trading
price of our common stock and the downturn in the U.S. stock and debt markets
could make it more difficult to obtain financing through the issuance of equity
or debt securities. Even if we are able to raise the funds required, it is
possible that we could incur unexpected costs and expenses, fail to collect
significant amounts owed to us, or experience unexpected cash requirements that
would force us to seek alternative financing. Further, if we issue additional
equity or debt securities, stockholders may experience additional dilution or
the new equity securities may have rights, preferences or privileges senior to
those of existing holders of our common stock. If additional financing is not
available or is not available on acceptable terms, we will have to curtail our
operations again.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires management of the Company to
make assumptions, estimates and judgments that affect the amounts reported in
the financial statements, including the notes thereto, and related disclosures
of commitments and contingencies, if any. The Company considers its critical
accounting policies to be those that require the more significant judgments and
estimates in the preparation of the Company's financial statements, including
the following: valuation of inventories and intangible assets, valuation of
stock options and warrants, and valuation of all accrued liabilities including
payroll taxes and other contingent liabilities. Management relies on historical
experience and on other assumptions believed to be reasonable under the
circumstances in making its judgment and estimates. Actual results could differ
materially from those estimates.

ITEM 3 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we conducted an evaluation,
under the supervision and with the participation of our chief executive officer
and principal financial officer of our disclosure controls and procedures (as
defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon
this evaluation, our chief executive officer and principal financial officer
concluded that our disclosure controls and procedures are effective to ensure
that information required to be disclosed by us in the reports that we file or
submit under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission's rules and forms. There was
no change in our internal controls or in other factors that could affect these
controls during our last fiscal year that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.


                                       9
<PAGE>

                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

From time to time, the Company is a party to litigation or other legal
proceedings that it considers to be a part of the ordinary course of its
business. The Company is not involved currently in legal proceedings that could
reasonably be expected to have a material adverse effect on its business,
prospects, financial condition or results of operations except as set forth
below. We may become involved in material legal proceedings in the future.

ITEM 2 - CHANGES IN SECURITIES

In connection with a private placement, on January 24, 2005 the Company issued
10,000,000 shares of its common stock at $0.002 per share realizing $20,000.

On February 1, 2005, the Company issued 2,500,000 shares of its preferred stock
at $0.008 per share as payment of $20,000 against loans payable - stockholders
and accrued expenses - stockholders.

On March 5, 2005, Amazing, a subsidiary of the Company, entered into an
Agreement of Sale with Nature's Backyard, Inc., whereby Amazing agreed to buy
all intellectual property, permits, patents (granted, pending, or applied for),
trademarks, processes, formulation, exact ingredients, precise way of
manufacturing, and related items of the "Slim Cookie", a product for weight loss
and lowering cholesterol. The purchase price is as follows: (a) Payment of
$1,000 and the issuance of 200,000 shares of common stock on signing the
agreement, (b) 300,000 shares of common stock upon signing and filing of a
provisional patent application by the Company, (c) 100,000 shares of common
stock upon the issuance of a patent by the U.S. Patent and Trademark Office, (d)
payment of $4,000 not more than 60 days from the execution of the Agreement, and
(e) payment of $15,000 within 270 days of the execution of the Agreement.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

None

ITEM 6. - EXHIBITS

      (a) Exhibits

      31.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            302 of the Sarbanes-Oxley Act of 2002.

      32.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.


                                       10
<PAGE>

                                   SIGNATURES

      In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                              ADVANCED PLANT PHARMACEUTICALS, INC.


                              By:  /s/ David Lieberman
                                   ---------------------------------------------
                                   David Lieberman, Chief Executive Officer and
                                   Principal Financial Officer


Dated: May 20, 2005


                                       11